--- title: "IGC Pharma (IGC) news: offering and settlement" url: "https://aibio.space/companies/igc-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IGC offering and settlement news: IGC Pharma agrees to sell 779,997 shares at $0.30 in direct offering. IGC Pharma, Inc. (AMEX: IGC), United States." --- IGC IGC Pharma, Inc. AMEX · United States # IGC Pharma (IGC) news IGC offering and settlement news Financings · 2026-07-06 ## [IGC Pharma issues shares to two officers at $0.27 to settle $1,154,210 owed to them](https://aibio.space/news/igc-pharma-issues-shares-two-officers-0-27-settle-1-154-210-owed-them/) The CEO and the principal financial officer paid for the shares by cancelling amounts the company owed them, including personal cash advances. IGC Pharma paid no cash. ## Latest IGC Pharma news 1. 2026-06-05 Debt Financing [IGC Pharma extends $12,000,000 bank credit facility with O-Bank](https://aibio.space/news/igc-pharma-extends-12-000-000-bank-credit-facility-o-bank/) IGC Pharma has extended its $12,000,000 bank facility with O-Bank, and the facility fee rises from $48,000 to $60,000. The filing gives no amount drawn and no interest rate. 2. 2026-04-20 Debt Financing [IGC Pharma sells promissory notes to FirstFire and Vanquish Funding for $307,000 and $207,000](https://aibio.space/news/igc-pharma-sells-promissory-notes-firstfire-vanquish-funding-307-000/) The notes mature in 2027 and carry 12% interest. They can convert into common stock at 75% of the lowest trading price in the prior ten trading days, and only after an event of default. 3. 2026-01-06 Financings [IGC Pharma agrees to sell 779,997 shares at $0.30 in direct offering](https://aibio.space/news/igc-pharma-agrees-sell-779-997-shares-0-30-direct-offering/) The registered direct offering is expected to bring in about $234,000 before expenses. IGC Pharma says it will use the money for working capital and general corporate purposes. 4. 2025-11-14 Mergers [IGC Pharma subsidiary closes Vancouver facility asset sale valued at about $2.7 million](https://aibio.space/news/igc-pharma-subsidiary-closes-vancouver-facility-asset-sale-valued/) Holi Hemp LLC sold equipment, inventory and operating assets for an agreed fair value of about $2.7 million, but the consideration was supply rights and a contingent payout, with no cash. The pro forma statements show a non-cash gain of $1,051 thousand that narrows a reported quarterly loss to $548 thousand. 5. 2025-11-14 Mergers [IGC Pharma unit sold Vancouver facility assets for supply rights, not cash](https://aibio.space/news/igc-pharma-unit-sold-vancouver-facility-assets-supply-rights-not-cash/) Holi Hemp LLC completed the disposition on September 29, 2025. IGC Pharma filed pro forma financial statements showing a $1,051 thousand gain. 6. 2025-09-19 Financings [IGC Pharma files to sell up to $11,309,229 of stock at market](https://aibio.space/news/igc-pharma-files-sell-up-11-309-229-stock-market/) IGC Pharma, Inc. set the amount under a $60,000,000 at-the-market sales agreement with A.G.P./Alliance Global Partners. The cap follows a rule that limits small companies to one-third of their public float. ## IGC Pharma at a glance - **Ticker**: IGC - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $354,000 ### Related companies - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [Kodiak Sciences](https://aibio.space/companies/kodiak-sciences/) NASDAQ: KOD - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) OTC: MCET - [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) NASDAQ: MNPR - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Equillium](https://aibio.space/companies/equillium/) NASDAQ: EQ - [Lexeo Therapeutics](https://aibio.space/companies/lexeo-therapeutics/) NASDAQ: LXEO ### Also on AMEX - [NanoViricides](https://aibio.space/companies/nanoviricides/) NNVC - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) RGNT - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) MAIA - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AIM - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) PTHS - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) PLX ## What IGC Pharma does IGC Pharma, Inc. is a Maryland corporation focused on Alzheimer's disease. Its lead drug candidate, IGC-AD1, is a CB1 receptor partial agonist in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial named CALMA, which studies agitation in Alzheimer's patients. The company says IGC-AD1 has progressed through preclinical evaluations and a successful Phase 1 safety trial. Interim data from the trial show a statistically significant reduction in agitation compared to placebo within the first 2-6 weeks of treatment, and a clinical and statistically significant reduction in sleep disturbances. The company's early-stage pipeline includes preclinical candidates TGR-63, LMP, IGC-M3 and IGC-1C for Alzheimer's disease, and IGC-1A for metabolic disorders. During fiscal 2025 it reassessed its reportable segments and now operates as a single reportable segment focused on Life Sciences. The company uses artificial intelligence and machine learning models, including a tool called MINT-AD, to support early detection of Alzheimer's disease, and it reports 31 patent filings. Its fiscal year ends March 31. | Product or program | What it is | Stage | |---|---|---| | IGC-AD1 | CB1 receptor partial agonist for agitation in Alzheimer's dementia | Phase 2 clinical trial (CALMA study) | | TGR-63 | Disrupts amyloid-beta plaque formation in early to moderate Alzheimer's disease | Preclinical | | LMP | Targets neuroinflammation, neurotransmitter imbalance and inflammasome-3 in Alzheimer's disease | Preclinical | | IGC-M3 | Inhibits amyloid-beta plaque aggregation in early-stage Alzheimer's disease | Preclinical | | IGC-1C | Targets tau protein phase separation; potential GLP-1 receptor agonist | Preclinical | | IGC-1A | Potential GLP-1 and GIP receptor agonist for type 2 diabetes and obesity | Preclinical | Summarised from the company's [10-K filed Jun 27, 2025](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm). ## IGC Pharma annual financials | Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 | |---|---|---| | Revenue | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | | Research and development | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | [$3.8 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | | Net income (loss) | [-$7.1 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | [-$13.0 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | | Cash from operations | [-$4.8 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | [-$5.2 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | | Cash and equivalents | [$405,000](https://www.sec.gov/Archives/edgar/data/1326205/000118518525001752/) | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1326205/000118518525001752/) | [$0](https://www.sec.gov/Archives/edgar/data/1326205/000118518524000650/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $331,000, plus short-term investments of $23,000, $354,000 in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about IGC Pharma Has IGC Pharma raised money recently? Our latest story on this, dated Jan 6, 2026: "IGC Pharma agrees to sell 779,997 shares at $0.30 in direct offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/igc-pharma-agrees-sell-779-997-shares-0-30-direct-offering/). Has IGC Pharma settled a lawsuit? Our latest story on this, dated Jul 6, 2026: "IGC Pharma issues shares to two officers at $0.27 to settle $1,154,210 owed to them". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/igc-pharma-issues-shares-two-officers-0-27-settle-1-154-210-owed-them/). What is the ticker symbol of IGC Pharma? IGC Pharma, Inc. trades under the ticker IGC on AMEX. Where is IGC Pharma listed? IGC Pharma, Inc. is listed on AMEX. Our directory also records these other listings: GETTEX:IGS1; LS:A1T87A; LSX:A1T87A. What is the SEC CIK of IGC Pharma? The SEC Central Index Key (CIK) for IGC Pharma, Inc. is 1326205. Its filings are on SEC EDGAR. How many shares does IGC Pharma have outstanding? 103,384,008 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is IGC Pharma listed under? Our directory records IGC Pharma, Inc. under United States. What does IGC Pharma do? Our directory classifies IGC Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of IGC Pharma? The ISIN recorded for IGC Pharma, Inc. is US45408X3089. Does aibio.space cover IGC Pharma? aibio.space lists IGC Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is IGC Pharma incorporated? SEC records list its state or country of incorporation as MD. What does IGC Pharma develop? IGC Pharma, Inc. is a Maryland corporation focused on Alzheimer's disease. Its lead drug candidate, IGC-AD1, is a CB1 receptor partial agonist in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial named CALMA, which studies agitation in Alzheimer's patients. What is IGC-AD1 from IGC Pharma? IGC-AD1: CB1 receptor partial agonist for agitation in Alzheimer's dementia Stage: Phase 2 clinical trial (CALMA study). What is TGR-63 from IGC Pharma? TGR-63: Disrupts amyloid-beta plaque formation in early to moderate Alzheimer's disease Stage: Preclinical. What was IGC Pharma's revenue last year? $1.3 million for the fiscal year ended Mar 31, 2025, as reported to the SEC. ## Investor discussion: IGC Pharma Members talk about IGC Pharma (IGC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at IGC Pharma, newest first. Each line links the filing it comes from. 1. 2026-07-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002808/igc8k070626.htm) 2. 2026-01-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000030/igc424b5010526.htm) 3. 2025-11-14 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1326205/000118518525001713/igcex99-1.htm) 4. 2025-09-19 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1326205/000118518525001235/igc424b5091925.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:IGC on TradingView](https://www.tradingview.com/symbols/AMEX-IGC/). ## SEC filings and registration - **SEC name**: IGC Pharma, Inc. - **CIK**: 1326205 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: IGC (NYSE) - **State or country of incorporation**: MD - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 10224 FALLS ROAD, POTOMAC, MD, 20854 - **Phone**: 301-529-4996 - **Shares outstanding**: 103,384,008 as of 2026-08-05 (10-Q filed 2026-08-14) - **Former names**: India Globalization Capital, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1326205/000118518526004896/igcdef14a102126.htm) filed 2026-10-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326205/000118518526003544/igc10q063026.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igc8k071326.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002808/igc8k070626.htm) filed 2026-07-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/igc8k060826.htm) filed 2026-06-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1326205/000118518526001885/igc10q033126.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1326205/000118518526001437/igc8k200426.htm) filed 2026-04-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1326205/000118518526001146/igc8k033026.htm) filed 2026-03-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001326205), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details IGC Pharma, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker IGC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: IGC Pharma, Inc. - **Ticker**: IGC - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US45408X3089 - **Other listed symbols**: GETTEX:IGS1; LS:A1T87A; LSX:A1T87A - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-IGC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/igc-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "IGC Pharma (IGC) news: offering and settlement", 2026-10-31, https://aibio.space/companies/igc-pharma/